Trending...
- New Home Helpers Home Care Office Opens in Farmington
- IOTech announces a major new release of Edge XRT, its software platform for time-critical OT systems
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
SAN JOSE, Calif. - Michimich -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Michimich.com
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Michimich.com
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Michimich.com
- In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
- New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
- DEER CAMP® Coffee Crafts Cold Brew Beef Jerky
- GreenPath Financial Wellness' Empathy-Focused Financial Coaching Program Delivers Results
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Michimich.com
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- CIMdata Announces September Date for the next Product Lifecycle Management Certificate Program
- Michael Griffie for Congress Campaign Builds Momentum with Detroit News Endorsement
- ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent
- Health Advisory: Protecting Yourself and Others from Monkeypox
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
Filed Under: Manufacturing
0 Comments
Latest on Michimich.com
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- New Home Helpers Home Care Office Opens in Farmington
- CHASM unveils highly-respected CEO John Kawola as its first independent board member
- Hygieia Advances its Global Business Development Activities with d-Nav® Program in Israel
- CIMdata Releases White Paper on Supplier Collaboration in Aerospace and Defense
- IOTech announces a major new release of Edge XRT, its software platform for time-critical OT systems
- Connect Fibre Partners With Linksys and Axiros
- Bacchus Wine & Spirits Jumps To Elite 'Top 20' Position In Beverage Dynamics Top 100 Retailers for 2022
- PermaTherm 2022 Family Fun Day
- New development in Ramsey called Williams Woods!
- Tarps Now® Issues Guide for Protective Mesh Tarp Applications
- Leading OEMs to showcase chassis updates at NTEA's 2022 Commercial Vehicle Upfitting Summit
- Top New Jersey Engagement Shoot Locations and couples who totally nailed it
- BEC Technologies RidgeWave® 7000 Series Achieves AT&T Certification
- OneStream Names KPMG in Canada 2022 Power of the Platform Winner
- Alta Vista Technology name a Top 100 Cloud Accounting VAR in North America
- Otava Named to the 2022 CRN Solution Provider 500 List